Nominations Open for 2009 Landon-AACR Prizes for Scientific Achievement in Cancer Research
August 6, 2008
Deadline for Nominations is August 25, 2008
PHILADELPHIA - The American Association for Cancer Research (AACR) is currently accepting nominations for two of the world's most prestigious awards granted to cancer researchers from a professional society of their peers. The Kirk A. Landon - AACR Prize for Basic Cancer Research and the Dorothy P. Landon-AACR Prize for Translational Cancer Research are awarded to outstanding scientists who have made seminal cancer research discoveries at the cutting edge of scientific novelty and significance. Such discoveries must have accelerated progress against cancer and must have implications for future discoveries and contributions to cancer research. Each prize consists of $100,000, which includes a $15,000 honorarium and an $85,000 grant for direct research expenses.
Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Candidates must be active researchers and have a record of recent scientific publications.
Each prize recipient will present a 50-minute scientific lecture at the AACR 100th Annual Meeting, April 18 - 22, 2009, in Denver, Colorado to stimulate new thinking among their colleagues in basic and translational cancer research. The recipients will also participate in the Annual Landon-AACR Prize Symposium to be held at the University of Miami Sylvester Comprehensive Cancer Center in January 2010.
The 2008 Kirk A. Landon-AACR Prize for Basic Cancer Research was awarded to Arnold J. Levine, Ph.D., Professor, Institute for Advanced Study and Cancer Institute of New Jersey. Levine was recognized for his work in establishing p53 as a tumor suppressor, one of the body's most important defenses against many forms of cancer, and for his extraordinary contributions to our understanding of the molecular basis of cancer.
The 2008 Dorothy P. Landon-AACR Prize for Translational Cancer Research was awarded to John Mendelsohn, M.D., President and Professor of Cancer Medicine at The University of Texas M. D. Anderson Cancer Center, for his pioneering translational research that led to the discovery of a new class of agents to treat cancer and for his landmark contributions to our growing knowledge of targeted cancer therapies.
For more information on eligibility criteria, the nomination process and other details about the Landon-AACR Prizes for Basic and Translational Cancer Research please visit our website. Submissions for these awards should be sent to email@example.com. Inquiries regarding these awards should be directed to firstname.lastname@example.org. The nomination deadline is Monday, August 25, 2008 at 4:00 p.m., U.S. Eastern Time.
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and 80 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. The AACR also publishes CR, a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.